Osteopontin (OPN) is a secreted
phosphoprotein which mediates
tumorigenesis, local growth, and
metastasis in a variety of
cancers. It is a potential therapeutic target for the regulation of
cancer metastasis.
RNA aptamer technology targeting OPN may represent a clinically viable
therapy. In this study, we characterize the critical sequence of an
RNA aptamer, termed OPN-R3, directed against human OPN. It has a K(d) of 18 nmol/l and binds specifically to human OPN as determined by
RNA electrophoretic mobility assays. In MDA-MB231 human
breast cancer cells examined under fluorescence microscopy, OPN-R3 ablates cell surface binding of OPN to its cell surface CD44 and
alpha(v)beta(3) integrin receptors. Critical enzymatic components of the OPN signal transduction pathways, PI3K, JNK1/2, Src and Akt, and mediators of extracellular matrix degradation,
matrix metalloproteinase 2 (MMP2) and uroplasminogen activator (uPA), are significantly decreased following exposure to OPN-R3. OPN-R3 inhibits MDA-MB231 in vitro adhesion, migration, and invasion characteristics by 60, 50, and 65%, respectively. In an in vivo xenograft model of
breast cancer, OPN-R3 significantly decreases local progression and distant
metastases. On the basis of this "proof-of-concept" study, we conclude that
RNA aptamer targeting of OPN has biologically relevance for modifying
tumor growth and
metastasis.